alteplase

Low-dose intracoronary alteplase unlikely to improve outcomes in STEMI patients treated with primary PCI

1. In this randomized controlled trial, low-dose intracoronary alteplase given early during primary percutaneous coronary intervention (PCI) for acute ST-Elevation Myocardial Infarction (STEMI) did not reduce microvascular obstruction. 2. Health related quality of life was not improved with low-dose intracoronary alteplase. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute coronary Czytaj więcej…